C18 C19 C20
Conditions
Interventions
Group 1: Patients with colorectal carcinoma stages I-IV
determination of the CETC number from residual tissue (blood): 1 week before the first treatment, and 2 weeks after the last treatment of a neoadjuvant chemotherapy respectively, and/or 1 week before
Sponsors
Universität Bayreuth
Eligibility
Sex/Gender
All
Age
35 Years to 100 Years
Inclusion criteria
Inclusion criteria: histologically verified, invasive colorectal carcinoma (C18, C19, C20); initial diagnosis; stage I-IV; medical treatment in the Hospital Bayreuth, only; minimum 2 blood withdrawals (before and after a guideline-conform radio/chemotherapy or surgery)
Exclusion criteria
Exclusion criteria: lack of consent; unrelated, preceding malignancies < 10 years before the diagnosis of the colorectal carcinoma; pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| CETC numbers in the course of guideline-conform treatment of colorectal carcinoma (stage I-IV) (Maintrac protocol); gene expression, tumorigenicity and invasivity of CETCs (and if applicable primary tumor cells) in the course of guideline-conform therapy of colorectal carcinoma (single cell picking, PCR, pysical and biochemical assays); overall survival (follow up after 3 and 5 years via cancer registry) and progression-free survival (follow up after 3 and 5 years via cancer registry) | — |
Secondary
| Measure | Time frame |
|---|---|
| Comparison of gene expression, tumorigenic and invasive properties of CETCs with those of primary tumor cells (single cell picking, PCR, physical and biochemical assays) | — |
Countries
Germany
Contacts
Public ContactAlexander Kiani
Klinik für Onkologie und Hämatologie Klinikum Bayreuth
Outcome results
None listed